Kliničke studije za Гојазност u državi Ajdaho
22 studija za Гојазност traži učesnike na lokacijama u državi Ajdaho.
Gradovi u državi Ajdaho
Zvanični tekst studije (na engleskom)
Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight
- Solaris Clinical Research, Meridian
Тражи се учесникФаза 3
Узраст од 18 до 99 · Оба пола · Ажурирано 9. 11. 2026. · NCT07871409A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Elite Clinical Trials, Blackfoot
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT07351058Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Solaris Clinical Research, Meridian
Тражи се учесникФаза 3
Узраст од 18 до 99 · Оба пола · Ажурирано 6. 11. 2026. · NCT07575399A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity
- Solaris Clinical Research (SCR), Meridian
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07843498A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- Family First Medical Center, Idaho Falls
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07392190Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Medical Research Partners, Ammon
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07353931Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Grand Teton Research Group, Idaho Falls
Тражи се учесникФаза 3
Узраст од 18 до 70 · Оба пола · Ажурирано 4. 11. 2026. · NCT06937099Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Grand Teton Research Group, Idaho Falls
Тражи се учесникФаза 3
Узраст од 18 до 70 · Оба пола · Ажурирано 4. 11. 2026. · NCT06937086A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Elite Clinical Trials, Rexburg
Тражи се учесникФаза 2
Узраст од 18 до 75 · Оба пола · Ажурирано 4. 11. 2026. · NCT06897475Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- High Desert Heart and Vascular, Meridian
Тражи се учесникФаза 3
Узраст од 18 до 99 · Оба пола · Ажурирано 29. 10. 2026. · NCT07037459Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Elite Clinical Trials - Blackfoot /ID# 282042, Blackfoot
Тражи се учесникФаза 2
Узраст од 18 до 75 · Оба пола · Ажурирано 27. 10. 2026. · NCT07752979A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Meridian
Тражи се учесникФаза 3Здраве особе су добродошле
Узраст од 18 до 79 · Оба пола · Ажурирано 20. 10. 2026. · NCT07654374A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Medical Research Partners, Ammon
Тражи се учесникФаза 2
Узраст од 18 до 75 · Оба пола · Ажурирано 8. 10. 2026. · NCT07589608A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Medical Research Partners, Ammon
Тражи се учесникФаза 2
Узраст од 18 до 75 · Оба пола · Ажурирано 7. 10. 2026. · NCT06143956Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Solaris Clinical Research, Meridian
Тражи се учесникФаза 3
Узраст од 18 до 99 · Оба пола · Ажурирано 5. 10. 2026. · NCT07684235A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- Solaris Clinical Research, Meridian
Тражи се учесникФаза 3
Узраст од 8 до 18 · Оба пола · Ажурирано 30. 9. 2026. · NCT07253285A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Boise
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 16. 9. 2026. · NCT07743450A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Boise
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 16. 9. 2026. · NCT07743463A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- High Desert Heart and Vascular PLLC, Meridian
- St. Luke's Idaho Cardiology Associates, Meridian
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 18. 8. 2026. · NCT07567001Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Meridian
- ACCOMPLISH-1 Research Site, Rexburg
Тражи се учесникФаза 3
Узраст од 18 до 79 · Оба пола · Ажурирано 10. 8. 2026. · NCT07654361Functional Improvement in OSA and COPD With a Telehealth LifeStyle and Exercise Intervention
- Boise VA Medical Center, Boise
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 22. 7. 2026. · NCT06390345A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- Elite Clinical Trials, Blackfoot
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 7. 2026. · NCT07481630Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.